KRRO
Korro Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.61
+4.73%Oct 23, 2026, 11:51 UTC
Korro Bio, Inc. shares rose 29.7% in the last session on above-average trading volume.
Source:Oct 22, 2026, 11:00 UTC
Korro Bio, Inc. said it expects to submit a regulatory filing for KRRO-111 in the first half of 2027.
Source:Oct 22, 2026, 11:00 UTC
Korro Bio, Inc. announced preclinical mouse-study results for KRRO-111, reporting more than 95% SERPINA1 mRNA editing, approximately sixfold higher total AAT, restoration of circulating functional M-AAT, and up to 95% reduction in pathogenic hepatic Z-AAT.
Source:Oct 5, 2026, 20:05 UTC
Korro Bio dosed the first cohort of participants in its Phase 1/2 ANCHOR clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia in urea cycle disorders and hepatic encephalopathy.
Source:Aug 6, 2026, 11:00 UTC
Korro Bio nominated KRRO-111 as a development candidate for the treatment of Alpha-1 Antitrypsin Deficiency.
Source:Aug 6, 2026, 11:00 UTC
Korro Bio received Orphan Drug Designation from the European Medicines Agency for KRRO-121 for patients with urea cycle disorders.
Source:Aug 6, 2026, 00:00 UTC
Korro Bio, Inc. exchanged 1,000,000 outstanding common shares for pre-funded warrants to purchase 1,000,000 new shares of common stock, with an exercise price of $0.001 per share, in a transaction with Venrock Healthcare Capital Partners entities on August 6, 2026.